GLP-1 Market
LLY $1166.51 ▼ -1.4% NVO $38.06 ▼ -1.3% PFE $28.37 ▼ -0.1% VKTX $26.65 ▼ -6.0% KLRA $10.77 ▼ -4.9% GPCR $22.31 ▼ -6.7% RHHBY $53.77 ▼ -0.6%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

N-Acetylcysteine Amide

Company
Nacuity Pharmaceuticals, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 14, 2026

Find a Clinical Trial Near Me

See recruiting studies for N-Acetylcysteine Amide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07710196

    A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

    Not yet reported Nacuity Pharmaceuticals, Inc. 80 participants Est. completion 2029-04 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Usher Syndrome
    View official trial listing →
  • Completed NCT NCT04355689

    Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome

    Not yet reported, Not yet reported Nacuity Pharmaceuticals, Inc. 49 participants Est. completion 2026-04-22 4 sites Stand-alone
    Other conditions: Usher Syndromes
    View official trial listing →
  • Completed NCT NCT05994534

    PK and PD Study of NPI-001 and Cysteamine Bitartrate

    Not yet reported, Not yet reported Nacuity Pharmaceuticals, Inc. 8 participants Est. completion 2026-05-26 1 site Stand-alone
    Other conditions: Cystinosis
    View official trial listing →
  • Not yet recruiting NCT NCT07290530

    24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

    Not yet reported Nacuity Pharmaceuticals, Inc. 80 participants Est. completion 2029-07 Stand-alone
    Obstructive sleep apnea Other conditions: Usher Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT07716865

    Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)

    Not yet reported Arctic Therapeutics 15 participants Est. completion 2027-01-31 1 site
    Other conditions: Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain, Hemorrhage Cerebral
    View official trial listing →
  • Active, not recruiting NCT NCT07741526

    Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)

    Not yet reported Arctic Therapeutics 33 participants Est. completion 2027-05-31 4 sites Stand-alone
    Other conditions: Alzheimer´s Disease
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: N-Acetylcysteine Amide, NPI-001

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.